Skip to main
VNRX

Volitionrx Limited (VNRX) Stock Forecast & Price Target

Volitionrx Limited (VNRX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VolitionRX Ltd is well-positioned for growth, supported by the successful launch and sale of its CE-Marked Nu.Q NETs automated assay, which has seen adoption across over 20 hospitals in 10 countries and multiple clinical indications. The strategic partnerships with industry leaders Werfen and Hologic for human diagnostics licensing are expected to enhance market penetration and facilitate broader access, particularly in the growth market of China. Additionally, the development of the Nu.Q Vet Feline Test promises to create a new recurring revenue stream in veterinary oncology, further expanding VolitionRX’s market reach in both human and animal diagnostics.

Bears say

VolitionRX Ltd faces increased dilution risk, which negatively impacts its valuation and financial outlook. The adjustment in price target from $5.00 to $3.00 reflects concerns over the sustainability of its business model and the potential for further capital raises. These factors contribute to a pessimistic view on the company's stock performance moving forward.

Volitionrx Limited (VNRX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Volitionrx Limited (VNRX) Forecast

Analysts have given Volitionrx Limited (VNRX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Volitionrx Limited (VNRX) has a Strong Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Volitionrx Limited (VNRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.